Drugs by condition
Drugs approved for schizophrenia
Last checked: Nov 19, 2026Source: FDA labels (openFDA), Drugs@FDAMethods & limitations
Brand-name drugs approved
38
Still marketed, NDA or BLA
Drug classes
4
Novel drugs
16
New molecular entities and new biologics
In development
26
Investigational drugs in Phase 2 or 3
Newest approvals
The most recently first-approved brand-name drugs for schizophrenia.
- Weltruza (Olanzapine) · Teva Oct 8, 2026
- Bysanti (Milsaperidone) · Vanda Pharms INC NovelFeb 20, 2026
- Cobenfy (Trospium Chloride, Xanomeline Tartrate) · Bristol-Myers NovelSep 26, 2024
- Erzofri (Paliperidone Palmitate) · Luye Innomind Pharma Jul 26, 2024
- Opipza (Aripiprazole) · Xiamen Lp Pharm CO Jul 22, 2024
All approved drugs for schizophrenia, by class
Every marketed NDA or BLA whose current FDA label names this condition in its Indications and Usage section, plus 228 generic labels. A drug can be approved for only part of a condition (one subtype or stage, or as add-on therapy), so check its label.
Atypical Antipsychotic (20)
- Lybalvi Olanzapine, Samidorphan L-Malate · Alkermes INC · 2021
- Caplyta Lumateperone Tosylate · Intra-Cellular · 2019
- Vraylar Cariprazine Hydrochloride · Abbvie · 2015
- Fanapt Iloperidone · Vanda Pharms INC · 2009
- Invega Paliperidone · Janssen Pharms · 2006
- Abilify Aripiprazole · Otsuka · 2002
- Geodon Ziprasidone Hydrochloride · Viatris · 2001
- Zyprexa Olanzapine · Cheplapharm · 1996
- Risperdal Risperidone · Janssen Pharms · 1993
- Clozaril Clozapine · Heritage Life · 1989
- Opipza Aripiprazole · Xiamen Lp Pharm CO · 2024
- Uzedy Risperidone · Teva · 2023
- Abilify Asimtufii Aripiprazole · Otsuka · 2023
- Secuado Asenapine · Hisamitsu · 2019
- Rexulti Brexpiprazole · Otsuka · 2015
- Versacloz Clozapine · Douglas Pharms · 2013
- Zyprexa Olanzapine · Cheplapharm · 2004
- Geodon Ziprasidone Mesylate · Viatris · 2002
- Zyprexa Zydis Olanzapine · Cheplapharm · 2000
- Risperdal Risperidone · Janssen Pharms · 1996
Cholinergic Muscarinic Agonist (1)
- Cobenfy Trospium Chloride, Xanomeline Tartrate · Bristol-Myers · 2024
Central alpha-2 Adrenergic Agonist (1)
- Igalmi Dexmedetomidine Hydrochloride · Teva · 2022
Class not listed in FDA's data (16)
- Bysanti Milsaperidone · Vanda Pharms INC · 2026
- Aristada Aripiprazole Lauroxil · Alkermes INC · 2015
- Latuda Lurasidone Hydrochloride · Sunovion Pharms INC · 2010
- Saphris Asenapine Maleate · Abbvie · 2009
- Seroquel Quetiapine Fumarate · Cheplapharm · 1997
- Weltruza Olanzapine · Teva · 2026
- Erzofri Paliperidone Palmitate · Luye Innomind Pharma · 2024
- Rykindo Risperidone · Shandong Luye · 2023
- Aristada Initio Kit Aripiprazole Lauroxil · Alkermes INC · 2018
- Invega Hafyera Paliperidone Palmitate · Janssen Pharms · 2015
- Abilify Maintena Kit Aripiprazole · Otsuka Pharm CO LTD · 2013
- Adasuve Loxapine · Nova Pneuma · 2012
- Zyprexa Relprevv Olanzapine Pamoate · Cheplapharm · 2009
- Invega Sustenna Paliperidone Palmitate · Janssen Pharms · 2009
- Seroquel Xr Quetiapine Fumarate · Cheplapharm · 2007
- Risperdal Consta Risperidone · Janssen Pharms · 2003
Drugs in development for schizophrenia
Investigational drugs FDA has not approved, in active or recent industry-sponsored Phase 2 and 3 trials for this condition. Phase 3 first.
- KarX-ECBMS-986519, Xanomeline Enteric-coatedPhase 39 trials
Bristol Myers Squibb · Alzheimer Disease, Alzheimer's Disease, Irritability Associated With Autism Spectrum Disorder
- SEP-363856UlotarontPhase 37 trials
Otsuka · Generalized Anxiety Disorder, Schizophrenia, Major Depressive Disorder
- NBI-1117568Phase 35 trials
Neurocrine Biosciences · Schizophrenia, Bipolar I Disorder, Mania
- LB-102Phase 34 trials
LB Pharmaceuticals Inc. · Schizophrenia, Bipolar I Disorder
- HS-10380Phase 33 trials
Jiangsu Hansoh Pharmaceutical Co., Ltd. · SCHIZOPHRENIA 1 (Disorder)
- SPG302TazbentetolPhase 33 trials
Spinogenix · Alzheimer Disease, Schizophrenia, Amyotrophic Lateral Sclerosis
- OLZSAM, ALKS 3831Phase 32 trials
Alkermes, Inc. · Bipolar I Disorder, Schizophrenia
- B2227Phase 31 trial
Bostal Drug Delivery Co., Ltd · Schizophrenia
- ML-007C-MAPhase 24 trials
MapLight Therapeutics · Psychosis Associated With Alzheimer's Disease, Schizophrenia
- ALTO-101Phase 21 trial
Alto Neuroscience · Schizophrenia, Cognitive Impairment
- BR5402APhase 21 trial
Boryung Pharmaceutical Co., Ltd · Schizophrenia
- BR5402A-1Phase 21 trial
Boryung Pharmaceutical Co., Ltd · Schizophrenia
- BR5402BPhase 21 trial
Boryung Pharmaceutical Co., Ltd · Schizophrenia
- BR5402B-1Phase 21 trial
Boryung Pharmaceutical Co., Ltd · Schizophrenia
- BR5402CPhase 21 trial
Boryung Pharmaceutical Co., Ltd · Schizophrenia
- BR5402C-1Phase 21 trial
Boryung Pharmaceutical Co., Ltd · Schizophrenia
- BR5402DPhase 21 trial
Boryung Pharmaceutical Co., Ltd · Schizophrenia
- BR5402D-1Phase 21 trial
Boryung Pharmaceutical Co., Ltd · Schizophrenia
- GXV813Phase 21 trial
Novartis · Schizophrenia
- KYN-5356Phase 21 trial
Kynexis B.V. · Cognitive Impairment Associated With Schizophrenia (CIAS)
2 discontinued brand-name drugs whose label still names it
More on schizophrenia: recruiting trials · published research
Related in psychiatry: Depression (major depressive disorder) · Bipolar disorder · ADHD · Anxiety disorders · Insomnia · Opioid use disorder · Alcohol dependence · Smoking cessation · PTSD · Postpartum depression
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.